Shoes, lockers and inflections
Evonik Industries, Adidas, AkzoNobel, R&S Group, Roche Holding, Allegro, Guerbet, Erste Group, Quadient, Siemens, ArcelorMittal, WPP
At Lux Opes, we break down companies into quick takes that get straight to the point - what is happening, why it matters, and what to watch next. We publish 2-3 times per week, depending on the news flow.
For the best reading experience, we recommend reading at Lux Opes
Financial KPIs
Companies covered in this edition: Evonik Industries, Adidas, AkzoNobel, R&S Group, Roche Holding, Allegro, Guerbet, Erste Group, Quadient, Siemens, ArcelorMittal, WPP

Evonik (EVK Germany): A suitor arrives in a windfall year
● NEUTRAL
BASF has approached Evonik, but this year's earnings jump comes largely from a supply shock outside Europe.
BASF confirmed on 25 September that it has held exploratory talks with Evonik and RAG-Stiftung, which owns about 44% of Evonik, about a possible takeover. Evonik's ad hoc statement that afternoon was cooler. It confirmed a non-binding approach regarding a voluntary public offer for all its shares, said that no talks were taking place and declined to comment further. RAG confirmed it had been contacted. Reuters reported on 28 September that Evonik had rejected the proposal as inadequate and put its value at about €10.3bn. None of the three parties has published a price, a financing plan or a timetable, and BASF only says the outcome is open and that it approaches acquisitions with discipline.
The timing makes any negotiation on value harder. In June Evonik lifted its 2026 adjusted EBITDA guidance to €2.0-2.2bn from €1.7-2.0bn, against about €1.9bn earned in 2025, and the second quarter then delivered €630m, up 24%. The company is open about the cause. Shipping disruption around the Arabian Peninsula left Asian competitors short of raw materials, and Evonik picked up volume and price, above all in amino acids for animal feed and in crosslinkers. Advanced Technologies lifted its margin to 20.2% from 17.6%. Custom Solutions, which gained less from the bottlenecks, moved only from 18.6% to 19.1%. Christian Kullmann called it a warm summer rain that leaves the industry's basic problems in place.
Our arithmetic shows how much of the year rests on that rain. The guidance midpoint implies about 10% EBITDA growth, and the cash conversion target of around 40% (37% in 2025) turns €2.0-2.2bn of EBITDA into only €0.8-0.9bn of free cash flow. Management behaves as if the windfall will pass. The Tailor Made efficiency program, which removes 2,800 jobs over 2024-2026, has been extended by roughly 3,200 more positions for 2027-2029, and the new CFO, Michael Rauch, says the priority is improving debt ratios. A buyer will price the normal earnings base, while Evonik will argue from the current one, and that gap is probably part of why talks stalled.
For Evonik holders the approach confirms that a large peer sees value in the portfolio, but it is not a transaction. With 44% of the capital, RAG decides whether anything happens, and it has said nothing beyond confirming contact. We would judge Evonik on what remains once the shipping disruption fades: whether the cost program lifts margins in Custom Solutions and the non-feed parts of Advanced Technologies, and whether cash conversion moves meaningfully above 40%. Until then the bid interest is a floor under sentiment, not a reason to own the shares.
Adidas (ADS Germany): Sales guidance up, profit guidance parked
● NEUTRAL
Local teams drive double-digit growth, but the unchanged €2.3bn profit target implies no acceleration in the second half.
Adidas runs the brand on a split model, and its 2025 annual report spells it out. Global franchises and the seasonal ranges are developed centrally, but each market team has its own design, development, sourcing and marketing resources to adapt the assortment and the way it goes to market. Besides Herzogenaurach there are creation centres in Portland and Los Angeles, Shanghai and Tokyo, and product is also created at source in Vietnam and Indonesia, the two biggest sourcing countries. The China team's Chinese New Year jacket is the company's favourite example of a locally made bestseller.
The second quarter shows where this pays off. Currency-neutral revenue rose 14% to a record €6.74bn. Latin America grew 28%, Japan and South Korea 18%, North America 17%, Greater China 15% and Emerging Markets 12%. Europe managed only 6% because Adidas held back on wholesale sell-in in a promotional market, although direct-to-consumer sales grew at double-digit rates there too. By product, apparel jumped 35% on World Cup kits and Originals, accessories 20%, and footwear just 1%, with deliberate restraint in lifestyle shoes. Gross margin improved 0.8 points to 52.5%, helped by full-price selling and a first small refund of US tariffs.
Profit is where the picture is less generous. Operating profit rose only 5% to €574m because marketing and point-of-sale spending climbed €212m to €924m for the World Cup. For the half, operating profit grew 11% to €1,279m, a 9.6% margin. Management raised the sales outlook to 9-10% currency-neutral growth but kept operating profit at about €2.3bn, 12% above the €2,056m of 2025. Our calculation puts implied second-half operating profit at roughly €1.0bn, about 13% above the same period of 2025, no faster than the first half even though a full extra point of sales growth has been added. Either Adidas is building in a cushion, or the extra revenue comes with costs it expects to carry.
The setup for 2027 is harder. The men's World Cup that lifted apparel this year will be a tough comparison, footwear is barely growing, and a model that hands more assortment decisions to local teams needs strict control of inventory and complexity to protect the margin. CFO Harm Ohlmeyer hands over to Birgit Kretschmer at the end of the year. On 15.9x 2026e P/E and 12.7x 2027e, the rating already counts on 2027 delivering the operating leverage this year's guidance holds back. We like the regional execution, but the next step needs footwear and operating leverage, and the unchanged profit guidance does not yet show either.
AkzoNobel (AKZA Netherlands): Paid to wait for the regulators
● POSITIVE
Shareholders backed the Axalta merger; a €2.5bn special dividend and Nippon's interest in Deco Paints support the case.
Both sets of shareholders approved the merger of AkzoNobel and Axalta at meetings on 5 August, so what remains is regulatory clearance and the usual closing conditions. The companies still aim to complete in late 2026 or early 2027. The UK Competition and Markets Authority formally opened its merger inquiry on 16 September, and its phase 1 decision is the next visible milestone.
The terms reward patience. Axalta holders receive 0.6539 AkzoNobel shares for each share, leaving AkzoNobel's owners with about 55% of the combined group, and before completion AkzoNobel pays a special dividend of €2.5bn minus any regular dividends paid in 2026. The new company will have one listing, in New York, after a temporary dual listing with Amsterdam, a Dutch holding company and two headquarters, with Greg Poux-Guillaume as CEO. Buybacks at both companies are suspended.
The cash payout is large next to AkzoNobel's own earnings. Standalone 2026 adjusted EBITDA is guided at €1.47bn or more, so the special dividend equals about 1.7 years of EBITDA, and the combined group expects net leverage of 2.0-2.5x at closing. The other side of the equation is the $600m of cost synergies, most of it within three years, which by our arithmetic is about 18% of the $3.3bn of combined adjusted EBITDA. If the remedies demanded by regulators stay narrow, that synergy pool is the main source of value. If they reach further into refinish or industrial coatings, some of it goes with the disposals.
AkzoNobel goes into the process in better shape than a year ago. In the second quarter organic sales grew 2% on pricing with stable volumes, operating income rose to €251m from €214m and the adjusted EBITDA margin improved 40 basis points, the fifth quarterly increase in a row. Leverage should be around 2x at year-end on a standalone basis.
Decorative Paints adds an option on top. In July AkzoNobel disclosed several conditional proposals from Nippon Paint valuing the division at €7.5bn on a cash-free, debt-free basis, said they significantly undervalued it and noted that the Axalta agreement prevents talks. That €7.5bn for one division is c.58% of AkzoNobel's €13.0bn group EV, which stands on 9.1x 2026e EV/EBITDA. That came a month after Nippon Paint and Sherwin-Williams withdrew a joint offer for the whole group. Two rejected approaches show that buyers exist for the paint brands, and the combined company can return to that question once the merger has closed.
R&S Group (RSGN Switzerland): A record backlog, an interim CEO and a steep second half
● NEUTRAL
Hitting 2026 guidance needs second-half sales about 30% above the first half, run by a CFO standing in as CEO.
R&S Group's guidance now asks a lot of the second half. First-half net sales fell to CHF179.2m from an adjusted CHF201.4m, a 9% organic decline at constant currency, and order intake dropped 10% on an adjusted basis to CHF216.8m. Around CHF15m of orders for a few larger projects were confirmed only after the balance sheet date. Management still expects CHF410-420m for the full year, subject to delivering large power transformers on time. That requires CHF231-241m in the second half, 29-34% more than in the first.
The order book makes the target possible on paper. The backlog reached a record CHF357.9m at the end of June against CHF305.7m a year earlier, about 1.5 times the sales the second half needs. The catch is that power transformer delivery schedules run well into 2027 and 2028, so a good part of that backlog cannot be billed this year. The guidance therefore depends on the timing of a small number of large units, which is the same issue that pushed sales out of the first half.
Profitability held up better than sales. EBITDA came to CHF34.0m, a 19.0% margin and inside the 19-21% range guided for the year, even though about 100 people have already been hired for the new power transformer plant in Łódź, which is due to start operating in the fourth quarter. Profit after tax fell to CHF22.4m from CHF28.8m. Free cash flow doubled to CHF11.5m, but the production equipment for Łódź arrives in the second half and will weigh on capital expenditure. Net debt rose to CHF71.4m after an CHF18.6m dividend and CHF12.5m of scheduled loan repayment, leaving leverage at 0.9x.
Leadership is the new risk. On 7 September the board and CEO Eduardo Terzi agreed that he would leave immediately, citing differing views on the leadership model and organisational setup, and CFO Matthias Weibel became CEO ad interim on top of his finance role. One person now runs both the second-half ramp and the plant start-up while the board looks for a successor. The capital markets day at Łódź on 4 November should show whether the plant is on time. We like the power transformer shift and the backlog, but until deliveries catch up and a permanent CEO is named, the full-year target looks more fragile than management's wording suggests.
Roche (ROG Switzerland): Fewer projects, higher hit rates, now the launches
● NEUTRAL
Roche cut its project count and lifted Phase III success above 80%; up to 20 new drugs could launch by 2030.
Roche's Pharma Day in London on 28 September was mostly about productivity, and the company brought numbers. Since the end of 2022 the number of projects in the pipeline has fallen 27% while its risk-adjusted value has risen 93%. The Phase III success rate improved from 65% in 2025 to more than 80% so far in 2026, development cycle times are about 19 months shorter than at the end of 2023, and some CHF1.6bn of savings has been moved into higher-priority research. Roche now counts up to 20 new molecular entities with launch potential by 2030, with two recent additions: tambotatug pelitecan in lung cancer and a VEGF x IL6 DutaFab in diabetic macular edema.
The list is broad. Oncology contributes giredestrant in breast cancer, divarasib in KRAS-mutated lung cancer and cevostamab in myeloma; neurology has trontinemab in Alzheimer's, fenebrutinib in multiple sclerosis and prasinezumab in Parkinson's; immunology has afimkibart in bowel disease; and cardiovascular and metabolism adds three obesity candidates, CT-996, enicepatide and petrelintide, plus zilebesiran for hypertension. Zemocimig, the planned successor to Hemlibra, has three Phase III trials running, including a head-to-head study against Hemlibra, with data due by the end of 2027. Launches that could come by then include giredestrant, fenebrutinib, divarasib in second-line lung cancer, sefaxersen in IgA nephropathy and afimkibart in ulcerative colitis.
The cost side is where our own reading of the slides is most encouraging. In the first half of 2026 Pharma spent CHF4.2bn on R&D, 34.7% of operating expenses, against 31.4% in the first half of 2023, while selling and administration fell to 40.5% of the total from 42.9%. Even so, the Pharma core operating margin rose to 53.0% from 49.6% over the same three years. More money is going to research and the margin still expands, so the extra spending is coming out of overhead instead of out of profit.
The test is what it always is in pharma: approvals and uptake. According to Börsen-Zeitung, Roche puts the sales it will lose to expiring patents at more than CHF6bn by 2030, and a pipeline counted in launch potential has to turn into prescriptions to replace that. Obesity is a crowded field in which Roche is late, and Alzheimer's has a long record of failure. Still, the evidence of better trial selection is concrete, and giredestrant and fenebrutinib give Roche two large launches before the patent losses peak. We see the pipeline as the strongest it has been in years, with the risk now in execution.
Allegro (ALE Poland): Poland pays for the expansion
● VERY POSITIVE
Polish GMV growth hit 12% and guidance rose again; international losses are growing more slowly than its sales.
Allegro's Polish marketplace is growing faster than at any point in recent years, and the company has raised its targets accordingly. In the second quarter Polish GMV rose 12.0% to PLN18.5bn, which Allegro says is more than three times the growth of nominal retail sales in the country. Polish revenue grew 14.4% to PLN3.17bn and adjusted EBITDA 11.3% to PLN1.15bn. For the group, GMV rose 14.4% to PLN19.6bn and adjusted EBITDA 11.5% to PLN1.03bn. Guidance now calls for 11-13% Polish GMV growth (previously 9-11%) and 11-14% growth in Polish adjusted EBITDA (previously 7-10%), with group GMV up 13-15% and group adjusted EBITDA up 13-17%.
The Polish economics are holding up despite the faster growth. By our calculation adjusted EBITDA came to 6.2% of GMV in the quarter and revenue, including other operating income, to about 17.1% of GMV. The extra services are what support that. Allegro Pay financed 16.4% of GMV after loan origination rose 35% to PLN4.5bn. Allegro Delivery now covers around half of parcel volumes through more than 40,000 lockers and almost 35,000 pick-up points, including over 11,000 One Boxes. Allegro Klik, a cashback product with PKO BP, gained more than 370,000 users in five months, and over 4,000 companies have signed up for merchant financing. Talks with InPost on an agreement running to 2031 include lower delivery prices, a new indexation formula and multi-year volumes.
Abroad, sales are still racing ahead of revenue. International GMV in the Czech Republic, Slovakia and Hungary jumped 82.4% to PLN1.06bn, but segment revenue rose 46.3% to PLN176m and the adjusted EBITDA loss widened 8.2% to PLN122.8m. That loss equals 11.6% of GMV, a much lower ratio than a year ago because GMV grew ten times faster than the loss. International GMV roughly doubled in the first ten weeks of the third quarter, Allegro expects to add almost PLN2bn of foreign GMV this year, and break-even is still targeted for 2029. A new office in Shenzhen is meant to tighten compliance among Chinese sellers at source.
CEO Marcin Kuśmierz names tariffs on Chinese platforms as one factor among several behind the upgrade, which means part of the Polish acceleration depends on trade policy. CFO Jon Eastick hands over to Katarzyna Ostap-Tomann, and a share buyback started in July. We think the mix is attractive: a domestic platform growing faster with stable margins and paying for an international business whose losses are shrinking relative to its size.
Guerbet (GBT France): The banks hold the timetable
● NEGATIVE
Raleigh remediation and China cut H1 profit; leverage is 5.3x and refinancing must be agreed by 31 October.
Guerbet's first half held revenue steady and lost money. Sales came to €379.2m, down 2.2% as reported and flat at constant currency and scope. EBITDA fell by €15.5m to €30.6m, an 8.1% margin, and the restated margin excluding restructuring was 9.1% against 12.9% a year earlier. The remediation plan at the Raleigh plant in North Carolina cost €14.3m in the half, mostly in outside technical experts. With €17.9m of provisions for the transformation plan, including a French redundancy scheme, the group posted an operating loss of €18.4m and a net loss of €32.7m.
The regions moved in different directions. EMEA grew 1.8%, with France up 9% now that the change in contrast agent supply has been absorbed. The Americas grew 1.2%, and the second quarter improved to 4.8% as Raleigh released more batches. Asia fell 5%, and 14% in the second quarter, because China is cutting healthcare spending and moving to volume-based procurement; Guerbet switched to direct sales there in August. Interventional radiology grew 4.7% on Lipiodol, diagnostic imaging slipped 0.9%.
The balance sheet is the immediate problem. Free cash flow was negative €30.2m as capital spending rose to €30.2m from €17.2m, and net debt climbed to €355.9m, giving leverage of 5.3 times. Lenders have waived the leverage covenant tests at June 2026, December 2026 and June 2027, but because the waivers came after the period end, €438.6m of debt sits in current liabilities. Against €132m of cash, maturities are €53.6m in the second half, €10m in 2027 and €275m in 2028. Guerbet wants refinancing terms agreed by 31 October. Equity is only c.22% of a €408m EV at 5.6x 2026e EV/EBITDA, so the refinancing terms will largely decide what is left for shareholders. Full-year free cash flow is guided at minus €50-70m, so by our calculation the second half burns another €20-40m.
The operating plan is unchanged. Raleigh should reach a normal batch release rate by the end of 2026, ready for a new FDA inspection, with normal operations through 2027. The 2026 targets stand: revenue stable or slightly lower, and a restated EBITDA margin of about 8% including around €35m of Raleigh costs, so roughly €21m of those costs still lie ahead. CFO Jérôme Estampes resigned and leaves at the end of December after finishing the bank talks, and Océane Mignot joined the executive committee as Chief Transformation Officer. Shareholders are in second place behind lenders until the refinancing terms are known, and we would wait for them.
Erste Group (EBS Austria): Buying more of Poland with its own capital
● NEUTRAL
Erste offers about PLN713 a share for up to 26% more of Erste Bank Polska, funded internally with CET1 above 14.25%.
Erste Group plans a voluntary cash tender for up to 26% of Erste Bank Polska, in which it bought a 49% controlling stake in January. The price will be the three-month average up to 28 September, the expected filing date, which Erste puts at about PLN713 per share, 22.1% above the PLN584 it paid for the original block. The goal is to go above 50% and no higher than 75%, in line with Erste's commitment to the Polish regulator to keep at least 25% of the bank in free float. The offer is due to open at the start of November, run for 30 days and settle in December.
The structure has an unusual condition. The tender needs enough acceptances to take Erste past 50%, a green light from Poland's KNF banking supervisor for crossing that line, and commitments from holders of at least 25% of the shares not to tender. If more than 26% of the capital is offered, Erste intends to declare the tender unsuccessful and stay at 49%. In other words, too much success kills the deal, so Erste has to line up long-term holders on the other side before the tender opens.
The financial logic is easy to measure. Going from 49% to 75% would raise Erste's share of the Polish bank's profit by 53%, and even the minimum outcome gives it majority control. Erste will pay entirely from internal resources and targets a CET1 ratio above 14.25% after the offer. CET1 stood at 15.2% at the end of June, down from 19.3% in December after the first acquisition, so by our arithmetic the tender can absorb at most about 95 basis points of capital. Management expects the deal to add to earnings per share from 2027.
Poland is already reshaping Erste's numbers. Erste Bank Polska brought €41.4bn of loans and €59.3bn of deposits, won more than 300,000 new customers in the first half and has been rebranded since April. It also brought costs: €98m of Polish bank tax in the first half and €302m of one-off risk provisions on first consolidation. Erste's 2030 ambition, to double earnings per share to more than €15 from an adjusted €7.72 in 2025, explicitly counts on 'inorganic optionality in Poland'. This tender is the first instalment of that plan. We think the price is acceptable for control, and the 75% cap and the capital floor keep it from becoming a strain on distributions.
Quadient (QDT France): Selling the lockers to fund the e-invoicing bet
● POSITIVE
The UK lockers sold for €65m and the rest is for sale; Digital must now nearly double its margin.
Quadient has finished its strategic review and decided to sell the whole Lockers business. The first piece went quickly: the UK open network, about 3,000 lockers, goes to IDS Holdco for an enterprise value of €65m after a competitive process, with completion expected before the January 2027 year-end. That alone takes guided leverage excluding leasing from about 1.5x to 1.2x. A sale process has started for the Japanese and North American networks, the largest and most profitable part, while the small European private network stays inside Mail.
The deal values installed base, not current profit. By our arithmetic the UK price works out at about €21,700 per locker. Lockers as a whole generated €114m of revenue in 2025, up 22.4%, at an EBITDA margin of 5.0%, or roughly €6m of EBITDA across 27,700 lockers. Exiting also removes about €120m of planned locker capital spending over five years, around €24m a year. Quadient will review its capital allocation once the remaining sale is done, weighing debt reduction, investment and shareholder returns.
What stays behind is a mail business in managed decline and a digital business growing into a regulatory opportunity. On the restated basis, first-half revenue was €448m, down 2.0% organically. Digital rose 6.7% to €146m, with subscription revenue up 9.5% and annual recurring revenue of €264m growing at an annualised 12.9%. Mail fell 5.7% to €302m but kept a 24.9% EBITDA margin. France's e-invoicing reform went live on 1 September; by 21 September more than 950,000 entities had registered through Quadient's Serensia platform and over 700,000 invoices had been processed. Second-quarter e-invoicing bookings in France rose eleven-fold, and smaller companies must start issuing e-invoices from September 2027.
The margin target is the stretch. Digital earned 14.5% in the first half, burdened by implementation costs for the go-live, yet the full-year target is above 19%. If second-half Digital revenue merely matches the first half, our calculation says the margin has to reach about 24% in those six months. By 2030 Quadient wants about €550m of Digital revenue at around 30% and €500m of Mail at 20-25%, which would make Digital close to 60% of group EBITDA against 22% in the first half. Free cash flow of €34m in the half and net debt of €683m leave room to wait for the locker proceeds. We like the direction, but the second half has to show the Digital margin step-up before the 2030 picture becomes credible.
Siemens (SIE Germany): Data centres fill the order book
● POSITIVE
Q3 orders hit a record €27.9bn with Smart Infrastructure up 42%; the backlog now covers 1.7 years of sales.
Siemens goes into its fiscal year-end with a record backlog and three businesses all growing. In the third quarter to June orders rose 14% on a comparable basis to €27.9bn, revenue rose 8% to €20.8bn and the book-to-bill ratio reached 1.34. The order backlog hit a record €132bn, which by our calculation is about 1.7 years of the €78.9bn revenue Siemens booked in fiscal 2025. Profit in the industrial business rose 25% to €3.5bn, a 17.3% margin against 14.9% a year earlier, and free cash flow climbed to €4.1bn.
Smart Infrastructure is where the change is largest. Its orders jumped 42% to €8.0bn, led by large electrification and electrical products orders from data centre customers in the US and Europe, and over nine months its data centre orders more than doubled to about €6bn. Revenue rose 13% to €6.4bn at a 20.0% margin. Management raised the division's 2026 guidance to 10-11% comparable growth and an 18.5-19.5% margin. The concentration cuts both ways: the electrical side of the AI build-out now drives Siemens' order growth, and a pause in that spending would show up here first.
Digital Industries has turned the corner on profit. Orders grew 9% and revenue 10% to €4.9bn each, software revenue rose 15% to €1.8bn and annual recurring revenue reached €5.7bn. Profit jumped 44% to €923m, an 18.7% margin, mostly thanks to software. The division's guidance of 7-10% growth and a 17-19% margin is unchanged. Mobility kept bookings high at €7.6bn, including €2.2bn for double-deck trains in Switzerland, €2.0bn for maintenance in the UK and €0.6bn for long-term service of battery trains in Germany, with an 8.6% margin.
After nine strong months Siemens raised its earnings per share before purchase price accounting to €11.20-11.50 from €10.70-11.10, a 45 cent increase at the midpoint, while keeping 6-8% comparable revenue growth and a book-to-bill above 1. Binding tax rulings now allow the spin-off of Siemens Healthineers to go ahead, and a buyback is running. For the fourth-quarter report in November the order trend in Smart Infrastructure matters more than the quarter's profit, because it tells us whether data centre demand is still broadening. We think the backlog gives Siemens a solid start to fiscal 2027.
ArcelorMittal (MT Netherlands): Writing off Kryvyi Rih
● VERY NEGATIVE
Missile strikes ended production in Ukraine; the $1bn charge is non-cash and the plant was a small part of group steel.
ArcelorMittal told the Ukrainian government on 25 September that it cannot restart ArcelorMittal Kryvyi Rih in a safe and sustainable way. The site was hit by four missile strikes in five weeks, the latest on 21 September, which killed five people and injured 17 employees, one critically. The company expects a non-cash impairment of about $1bn, mainly on property, plant and equipment, and will now concentrate on preserving the infrastructure while it discusses the plant's future with the government, so that a restart remains possible once the war ends.
For the group the site has become small in steel and larger in ore. Kryvyi Rih produced 1.69 million tonnes of steel in 2025 and its mines 7.6 million tonnes of iron ore. Against group output of 55.6 million tonnes of crude steel and 48.8 million tonnes of ore last year, our arithmetic puts the plant at about 3% of ArcelorMittal's steel but about 16% of its iron ore. The loss therefore matters more for the mining side of the business than for steel volumes, and it reduces the share of ore the group supplies to itself.
Financially, the closure ends a long drain. Since February 2022 ArcelorMittal has put more than $700m into the subsidiary to keep it running, which we calculate at roughly $150m a year on average. Some spending continues, because the infrastructure has to be maintained for a possible restart, but that should cost far less than funding a partly used integrated steelworks under bombardment. Locally, the closure hurts: the plant paid UAH8.5bn in taxes and duties in 2025.
The impairment recognises damage that the war had already done, and group revenue of $61.4bn last year puts the $1bn charge in proportion. We see little lasting effect on the group's earnings power from losing the steel volumes, though the lost ore and the uncertain cost of keeping the site mothballed are real. Any value in Kryvyi Rih now depends on a peace settlement and on rebuilding power and logistics in the region, and we would not count on it in any view of the group.
WPP (WPP UK): Retained clients have to do the heavy lifting
● NEGATIVE
Q2 improved to -2.8% like-for-like, but H2 guidance still means decline, and margins dip as WPP reinvests.
WPP's second quarter was better than its first, but the business is still shrinking. Revenue less pass-through costs fell 2.8% like-for-like to £2,485m in the quarter and 4.7% to £4,745m in the half, which by our arithmetic puts the first quarter at about minus 6.6%. WPP credits an improving trend at WPP Media and easier comparisons. The headline operating margin for the half was 8.4%, up 0.2 points like-for-like on lower severance and cost savings.
The detail shows where the improvement came from. WPP Media fell 5.4% in the half but only 2.8% in the second quarter, after minus 8.3% in the first, with existing clients spending more and a smaller drag from net new business. WPP Creative fell 4.9%, WPP Production grew 1.6%. By region North America fell 6.0% (Q2: minus 4.3%), EMEA 4.3% and the Middle East and Africa 9.2%. Asia-Pacific fell 3.8%, although China grew 15.6% in the second quarter on timing factors that will not repeat, and Latin America was back to growth in the second quarter. The top 25 clients were down 6.3% for the half and 3.2% in the second quarter, hurt by assignments lost last year.
New business is building. First-half wins included consolidated mandates from Estée Lauder, Henkel and Wendy's, and WPP kept Skechers, Tesco, Huawei in China, L'Oréal in Australia and New Zealand, Uber in Asia-Pacific and Deutsche Bahn. Automotive, healthcare and government clients returned to growth, while consumer goods, tech and retail kept falling. The Elevate28 plan aims for £100m of savings this year and £500m of gross annualised savings by 2028, and disposals should bring in more than £200m in 2026.
The outlook is a slower decline, not growth. WPP expects like-for-like revenue less pass-through costs to fall by a low to mid-single-digit rate in the second half and a full-year headline margin of 12-13%, which means second-half margins down by up to about 200 basis points as it reinvests and rebuilds incentives. Adjusted operating cash flow before working capital should be £800-900m, adjusted net debt was £2,935m in June, and the 15p dividend is maintained. At 6.0x 2026e EV/EBITDA and 7.3x 2026e P/E (7.0x 2027e) the rating assumes no growth, and net debt of about three and a half years of that cash flow keeps the equity geared to any further client losses. Wins take time to show up in revenue, so the next quarters depend on retained clients spending more. We would want to see that before treating the second quarter as a turn.